Zydus Lifesciences Limited has informed the Exchange regarding a press release dated September 13, 2024, titled "Zydus announces exclusive licensing and supply agreement for two Gadolinium based Magnetic Resonance Imaging (MRI) injectable, contrast agents in the US.".
Press Release Sep 13 2024
Filed with NSE · · 3 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release regarding a new agreement. The company has entered into an exclusive licensing and supply agreement for two MRI contrast agents in the US market. Zydus will market and distribute these products, while Viwit Pharmaceuticals will handle manufacturing and regulatory submissions. This marks the introduction of Gadolinium based MRI contrast agents into Zydus' injectable portfolio for the US.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Sep 10 2024
- Zydus receives final approval from USFDA for Scopolamine Transdermal System 1 mg/3 days
- Press Release Aug 30 2024
- Press Release Aug 27 2024
- Press Release Aug 23 2024
Later from Zydus Lifesciences
- Press Release Sep 27 2024
- Press Release Sep 28 2024
- Press Release Oct 01 2024
- Press Release Oct 02 2024
- Press Release Oct 10 2024
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences